You are probably correct coppa1 although I hope we pessimists are wrong.
As posted, Cellmid will likely remain busy and productive while others are not. That is the key invest.ent case as I see it.
I would also like to see the supression of proteins and genes associated with the lung inflammation pathways of COVID-19 patients ageing explored scientifically.
Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement, page-822
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1199234 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 340000 | 1 |
View Market Depth
| Last trade - 16.12pm 09/07/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable